Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Other Non-Current Assets (2016 - 2025)

Tg Therapeutics has reported Other Non-Current Assets over the past 10 years, most recently at $1.3 million for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $1.3 million for Q4 2025, down 35.29% from a year ago — trailing twelve months through Dec 2025 was $1.3 million (down 35.29% YoY), and the annual figure for FY2025 was $1.3 million, down 35.29%.
  • Other Non-Current Assets for Q4 2025 was $1.3 million at Tg Therapeutics, down from $2.0 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for TGTX hit a ceiling of $2.2 million in Q2 2024 and a floor of $1.3 million in Q1 2021.
  • Median Other Non-Current Assets over the past 5 years was $1.3 million (2023), compared with a mean of $1.4 million.
  • Biggest five-year swings in Other Non-Current Assets: skyrocketed 68.49% in 2024 and later crashed 38.93% in 2025.
  • Tg Therapeutics' Other Non-Current Assets stood at $1.3 million in 2021, then grew by 0.71% to $1.3 million in 2022, then grew by 0.94% to $1.3 million in 2023, then surged by 61.4% to $2.1 million in 2024, then crashed by 35.29% to $1.3 million in 2025.
  • The last three reported values for Other Non-Current Assets were $1.3 million (Q4 2025), $2.0 million (Q3 2025), and $1.3 million (Q2 2025) per Business Quant data.